Aminoglycosides (AGs) are highly potent antibacterial agents, which are known to exert their deleterious effects on bacterial cells by interfering with the translation process, leading to aberrant protein synthesis that usually results in cell death. Nearly 45 years ago, AGs were shown to induce read-through activity in prokaryotic systems by selectively encoding tRNA molecules at premature termination codon (PTC) positions; resulting in the generation of full length functional proteins. However, only in the last 20 years this ability has been demonstrated in eukaryotic systems, highlighting their potential as therapeutic agents to treat PTC induced genetic disorders. Despite the great potential, AGs use in these manners is quite restricted due to relatively high toxicity values observed upon their administration. Over the last few years several synthetic derivatives were developed to overcome some of the enhanced toxicity issues, while in parallel showed significantly improved PTC suppression activity in various in-vitro, ex-vivo and in-vivo models of a variety of different diseases models underling by PTC mutations. Although these derivatives hold great promise to serve as therapeutic candidates they also demonstrate the necessity to further understand the molecular mechanisms of which AGs confer their biological activity in eukaryotic cells for further rational drug design. Recent achievements in structural research shed light on AGs mechanism of action and opened a new avenue in the development of new and improved therapeutic derivatives. The following manuscript highlights these accomplishments and summarizes their contributions to the state of art rational drug design.
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Aminoglycosides and genetic diseases
AGs antibacterial activity as miscoding agents has been extensively investigated over the last several decades. However, nearly 2 decades after the discovery of streptomycin, it was discovered that AGs are able to suppress premature termination codons (PTCs), restoring full-length protein production in Escherichia coli (E. coli) 10 . PTCs are genetic code mutations usually occurring due to base pair insertions, deletions, or substitutions that result in the replacement of an amino-acid codon in DNA by one of the three universal stop codons (TAA, TGA or TAG). These mutations generally lead to the production of truncated, nonfunctional proteins (Fig. 2) . In humans, PTCs have been linked to nearly 2,000 genetic disorders, such as cystic fibrosis (CF), Duchenne muscular dystrophy (DMD), ataxiatelangiectasia (AT), Hurler syndrome (HS), Rett syndrome, Usher syndrome (USH), Hemophilia A, Hemophilia B and Tay-Sachs 11, 12 . For many of these diseases there is presently no effective treatment.
In the last several years, a new therapeutic strategy has suggested the use of PTC suppression in the treatment of PTC induced genetic disorders 13 . This therapeutic strategy, [34] [35] [36] . The resulting data supported the previous findings and highlighted AGs as possible candidates for PTC suppression therapy. However, it also emphasized the complexity of the mechanisms of which these agents induce their therapeutic effects. For example, it has been noticed that the identity of the PTC affects the efficacy of 4 PTC suppression (TGA > TAG > TAA). In addition, the nucleotides located immediately downstream of the stop codon in the mRNA template (+4 position), also seem to determine the read-through potential (C > U > A ≥ G) as well as those located one residue upstream to the codon triplet (-1 position), where U seemed to induce the higher read-through levels. The local sequence context around the PTC and its position within the gene sequence where also
shown to affect the induced read-through levels 19, 37, 38 . In addition, recent publications demonstrated the ability of AGs to interfere with the nonsense mediated decay (NMD) system, implying that AGs not only induce read-through events on mutant mRNA upon translation, but also stabilize the survival of mutant mRNA species that are generally destined to degradation by the NMD apparatus. These activities are thoroughly discussed in recent review papers by Bedwell and coworkers 14 , and by Bidou and et al 15 , adding some more complexity to the already complex PTC read-through mechanism.
The chemical structure of AGs also seems to play a major role in their ability to interfere with translation termination. In fact, not all AGs are capable of inducing termination suppression, and the explanation for these facts yet remains rather obscure. In general, AGs containing a 6'-OH group in their first ring (such as G418 and paromomycin, Fig. 1 ) are superior to those enclosing an NH 2 moiety at the same position 19, 39 . These observations are usually subjected to one of the main differences between their putative binding sites in eukaryotic vs. prokaryotic systems: the 1408 position (E. coli numbering). It has been well documented that an A1408G mutation in bacteria confers resistance to AGs, and that higher levels of antibacterial resistance are usually observed towards AGs containing an amino moiety in their 6' position 40, 41 . To explain these observations it has been suggested that, while both 6'-OH and 6'-NH 2 can form H-bond interactions with A1408 in bacterial ribosomes, the 6'-NH 2 derivatives are prevented of such interactions with G1408 in eukaryotic ribosomes due to electrostatic repulsion between the positively charged nitrogen atom of the guanine residue and the 6'-NH 3 + of AGs.
The fact that eukaryotic ribosomes contain a guanine residue in the corresponding position might explain the higher activity observed in the 6'-OH derivatives. Very recent crystal structures of complexes of G418 with native vs. mutant bacterial binding sites suggested a structural explanation for the 6'-OH selectivity at the molecular level (Fig. 3 ) 42 .
In addition, a recent paper published by Baasov and coworkers 43 supplemented the structural basis for AG selectivity to Leishmania, a eukaryotic parasite of which AGs binding site differs only in one nucleotide when compared to human (U1409 in Leishmania vs. C1409 in humans, Fig. 4 ). This work did not only highlight the differential selectivity of 6'-OH and 6'-NH 2 derivatives to eukaryotes, but also indicated for the first time that not all AGs are capable of inducing the same conformational change upon binding; implying that unlike in bacterial 5 species, in eukaryotes the binding affinity and the actual binding to the A-site does not necessary result in biological activity (a more detailed explanation will be presented in section 6). However, despite recent progress in the structural understanding of AGs structureactivity relationships in eukaryotes some questions still remain unanswered, and it is not yet understood, for example, why gentamicin, a 6'-NH 2 derivative confers some rather high readthrough activities in eukaryotes. Such questions might indicate that we are not yet able to fully understand AG activities in eukaryotes, thus add some more complexity to the effort towards rationally designing some new and improved derivatives.
Aminoglycosides toxicity
Despite the promising results indicating the great potential of using AGs to treat genetic disorders, their use for such therapeutic purposes is quite restricted nowadays. [57] [58] [59] [60] ; these recent works demonstrated the ability of some natural and synthetic derivatives to inhibit mitochondrial protein synthesis; apparently, due to the relatively high similarity the mitochondrial ribosome shares with their primary target site, the bacterial ribosome (Fig. 4) .
6
An alternative model highlights cytoplasmic protein synthesis inhibition as a potential trigger of a cellular pathway, similar to ribotoxic stress response, leading to hair cell apoptosis 61 and enhance their therapeutic value. In addition they gave rise to the development of some new and improved synthetic AG derivatives that selectivity target the cytoplasmic eukaryotic ribosome 59 , avoiding mitochondrial inhibition.
The challenges and development in designing some new and improved AG derivatives are discussed in the following section (section 4).
Challenges in the design of novel nonsense read-through inducers
Synthetic derivatives carrying an AG scaffold have been extensively investigated over the last few decades as potential therapeutic agents to be used for the treatment of bacterial infections 63 . These efforts resulted in the development of improved derivatives with reduced toxicity and enhanced ability to delay the emergence of resistance among bacterial species 64, 65 . These compounds were massively investigated in both biochemical and structural manners, and along with the molecular understanding of AGs mechanisms of action and resistance in bacterial species, opened a new avenue in the field of antibacterial therapy.
However, due to the limited information regarding their mechanism of action in eukaryotes as well as the higher complexity of these systems, when compared to the prokaryotic ones, only a few novel semi-synthetic derivatives have been suggested as efficient known to induce SMN expression in mutant cells 71, 72 . TC007 has later been reported to induce beneficial effects on muscle fiber size and gross motor function in SMN mice model 73, 74 . However, the synthetic derivatives tested within this assay were initially designed as Approximately one year later, our group reported the development of two new synthetic derivatives, as third-generation leads in which first two rings of G418 (ring I and ring II) were used as an AG scaffold ( Fig. 5 ; compounds 3 and 4, also named NB74 and NB84, respectively) 70 . These derivatives were designed to contain a 6'-(R)-methyl that we hypothesized to act as a pharmacophore in G418, but nevertheless, did not contain the garosamine 3 rd ring, which has been shown to enhance the toxicity of both G418 and gentamicin, the two structurally highly related AGs ( 82 , it has been shown that long-term administration of compound 4 maintains α-Liduronidase activity and GAG reduction in Idua tm1Kmke mice throughout a 28-week treatment
period. An examination of more complex MPS I-H phenotypes in Idua tm1Kmke mice following 28-weeks treatment with compound 4 revealed significant moderation of the disease in multiple tissues, including the brain, heart and bone, which are resistant to current MPS I-H therapies. It is noteworthy to mention that this study, performed by Bedwell and co-workers, represents the first demonstration that long-term nonsense suppression therapy can moderate progression of a genetic disease.
Continuous research in our lab has recently led to the development of new generations of synthetic derivatives which have not only been shown to be potent readthrough inducers with relatively low toxicity, but also to be highly selective towards the eukaryotic ribosome, lacking any antibacterial activity ( Fig. 5 ; compounds 5-12) 59, 66 . These derivatives, fourth-and fifth-generation leads, were developed by introducing of a new pharmacophore -5''-(R/S)-methyl. In general, compounds with 5"-(S)-methyl were more active than the corresponding diastereomers with 5"-(R)-methyl. Interestingly, compounds 10 and 12 were shown to have read-trough activity similar to G418 in both in-vitro and ex-vivo systems, but exhibited a significantly reduced cell toxicity. Furthermore, one of these lead structures, compound 9 (also named NB124) restored CFTR function to ~7% of wild type activity in primary human bronchial epithelial (HBE) CF cells (G542X/delF508), a highly relevant preclinical model with endogenous CFTR expression, and rescued CFTR function in a CF mouse model expressing a human CFTR-G542X transgene; efficacy was superior to gentamicin and exhibited favorable pharmacokinetic properties, suggesting in vitro results translated to clinical benefit in vivo 83 .
The reduced toxicity of the developed leads shown in Figure 5 was recently attributed to their high selectivity towards the cytoplasmic ribosome altogether with the reduced selectivity towards the mitoribosome 59 . In particular, this study provided for the first time the proof of principle that antibacterial activity and toxicity of AGs can be dissected from their PTC suppression activity. Furthermore, using a series of biochemical assays including protein translation inhibition tests in prokaryotic, eukaryotic and mitochondrial systems, it has been shown that the increased specificity towards cytoplasmic ribosome correlates with the increased PTC suppression activity and that the decreased specificity towards mitochondrial ribosome confers the lowered toxicity.
The above mentioned progress in designing synthetic derivatives (compounds 1-12, Fig. 5 ) with potent PTC suppression activity and low toxicity emerged from a very careful inspection of the structural elements which are highlighted as important for the biological activity and toxicity of AGs. Thus, the design and development of these new lead structures were realized by systematic fine-tuning structure-activity-toxicity relationship studies, and were based mainly on the previously reported biochemical and toxicity data on standard AGs.
The results obtained are indeed very encouraging, but unfortunately, "rational design" of synthetic AGs for suppression therapy is still far from being well established, mainly due to the lack of detailed information on the molecular mechanisms of AGs activity and toxicity in eukaryotic systems. As an example, our recent works demonstrated the importance of high selectivity towards the eukaryotic cytoplasmic ribosome for the development of therapeutic agents with reduced toxicity 59, 62 . However, compounds that exhibit an enhanced selectivity towards eukaryotic systems do not always exceed better read-through activity. The natural AG apramycin and the synthetic derivative NB33 (Fig. 6) were shown to exhibit a rather high selectivity towards eukaryotic systems; 84, 85 nevertheless, their measured read-through activity had appeared to be rather negligible 84 . These results are now better understood from 10 the molecular point of view by the differences inspected in the binding site conformations upon binding of read-trough inducers such as G418 vs. non-read-through inducers such as apramycin to their putative binding site in Leishmania 43 highlighting the importance of AG's ring I in binding eukaryotic species (a more detailed analysis will follow in section 6). Over the last several years a few more AG based synthetic derivatives have been evaluated as selective potent binders of eukaryotic systems [85] [86] [87] [88] . However, the estimation of their readthrough abilities is yet to be determined.
Further improvement and rational development of new read-through inducers requires the molecular understanding of the read-through mechanism in mammalian cells, and a better characterization of their putative binding sites. Unfortunately, very few indications regarding this field are available nowadays, and this experimental field still remains largely obscure.
The following sections will highlight the structural information available up to date in regarding to AGs and their putative binding sites within the eukaryotic and prokaryotic ribosomes.
Non-aminoglycoside read-through inducers
AGs are the most extensively investigated low molecular weight compounds, which are capable of enhancing read-through activities in eukaryotic systems 89 . However, a few additional non-AG compounds were recently highlighted as potential candidates for the suppression of PTCs in mammalian cells. Some of these agents were discovered in highthroughput screening (HTS) experiments that aimed at screening for non-AG-read-through inducers. Fig. 7A ) is an example of such candidate, that is now tested in several clinical trials for the treatment of various PTC induced genetic disorders such as CF, DMD, hemophilia A and B, and methylmalonic acidemia 90 . PTC124 has been discovered at PTC Therapeutics Inc. by screening a library of low molecular weight compounds using a luciferase based reporter system 90 . Out of nearly 1,000,000 compounds tested, PTC124 
PTC124 (Ataluren,
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Inc. 93, 94 . These findings suggested that PTC124 enhanced the basal luciferase activity invitro, rather than enhancing the read-through of PTC containing transcript; therefore, implied that the PTC124 elevated read-through levels were resulting from an experimental artifact.
Nevertheless, the well documented in-vivo evidences described above, along with more recent ex-vivo and in-vivo works relating to nonsense-mediated congenital Aniridia 95 and Usher syndrome 1c, 96 still highlight the great potential of using PTC124 for suppression therapy.
An additional screen performed by Du et al. 97 highlighted the use of a few more non-AG compounds in PTC suppression. The initial screen has been performed using 34,000
compounds, of which 12 were shown to enhance read-through levels in an enzyme-linked immunosorbent assay (ELISA)-based reporter system. Two compounds, RTC13 and RTC14 (Fig. 7B, 7C) were further identified as leading compounds that were used at micromolar concentrations to enhance read-through levels in both AT patients derived cell lines and DMD mice models 97 . The mechanism of which these compounds act to suppress PTCs is currently unknown. However, based on the structural similarity of these agents to PTC124, it is assumed that they share similar mechanism of action. RTC13 and RTC14 did not show any measurable toxic side effects upon their administration at read-through inducing levels to mammalian cells.
Two additional compounds, which are currently used as antibacterial agents, were recently evaluated as potential read-through inducers: negamicin (Fig. 7D) and tylosin ( Nevertheless, despite the promising results in the field of PTC repair by non-AG agents, many of these agents suffer from major drawbacks limiting the probability of using 12 them in the clinic. Macrolides, for example, are known to induce severe toxic effects in eukaryotes, which might limit their approval as chronic medications. In addition, both macrolides and Negamicin are highly active against bacterial species and this lack of selectivity to eukaryotes might induce some massive changes in the patient's flora on the long run. Furthermore, to our knowledge, no recent work was aimed at exploring the molecular mechanisms by which such compounds imply their therapeutic effects on PTC related illnesses, nor alternative synthetic derivatives were designed to try and improve the activity or reduce the toxicity of such agents. Such improvements will have to be further performed in such compounds to enable their usability for the treatment of genetic diseases.
The read-through mechanism
General aspects and gained knowledge from structural investigations of bacterial ribosomes.
In general, a read-through event is defined as encoding of a PTC by near cognate aminoacylated tRNA. Read-through events spontaneously occur in basal levels of less than 1% of translating PTC containing transcripts 89 . Therapeutic compounds inducing higher readthrough activity levels are believed to be able to enhance the chance of near-cognate (Fig. 8) .
At the atomic level, the above mentioned structural rearrangements upon codon recognition greatly differ while comparing the two translational factors. The binding of cognate tRNA to the decoding center in bacterial ribosomes induces the flip out of two evolutionary conserved adenine residues, A1492 and A1493 (E. coli numbering), located in the internal loop of Helix-44 (H44). These bindings also cause the universally conserved base G530 to switch from syn to anti conformations 105 . In their new conformations, these residues, A1492 and A1493, can tightly interact with the first two bases of the codon-anticodon helix and are therefore able to monitor and discriminate between Watson-Crick base pairing and mismatches (Fig. 8) . However, structural studies on RF binding to bacterial ribosomes [100] [101] [102] [103] [104] , demonstrated that unlike in the sense codon case, in termination complexes, only A1492 flips out of H44, leaving A1493 inside the helical core to establish stacking interactions with an adenine residue, A1913, located at Helix69 (H69) in the large ribosomal subunit (Fig. 8) .
These interactions are considered to be highly important for the proper termination of translation process 106, 107 .
AGs where long shown to stabilize the flipping out of the two conserved adenine residues upon binding to bacterial ribosomes (Fig. 9) (Fig. 8A) . As indicated from recent X-ray structures, the conformation obtained upon RF binding is far remoted, where only A1492 is partially flipped out from the helical core and A1493 maintains stacking interactions with A1913 of H69 (Fig. 8B) . The flipping out of A1493 upon AG binding might induce a steric clash with the RF backbone, thus limit its actual binding to the A-site (Fig. 9B) . In addition, the flipping out of A1493 prevents the stacking interactions with A1913 of H69 110 . Since the stacking interactions between A1493 and A1913 have been highlighted as important components of RF recognition by the ribosome, the prevention of such interaction and/or the suggested steric clash between A1493 and RF backbone due to AG binding, might add an additional explanation for AGinduced inhibition of RF binding. These structural indications suggest that the induced conformation upon AG binding acts simultaneously to inhibit RF binding while facilitating near-cognate tRNA incorporation to the A-site; therefore shifting the near-cognate tRNA-RF competitive equilibrium towards a read-through event. These mechanistic implications might also explain the ability of some aforementioned non-AG agents to enhance the basal readthrough events. Indeed, PTC124 and tylosin where shown to bind relatively to the peptidyl transferase center, which can introduce steric hindrance for RF binding, but not for tRNA 15 binding; meaning that read-through events might result from enhancing the probability of basal read-through via enlarging the tRNA chances to occupy the A-site upon RF competition.
Eukaryotic ribosomes: status and read-through implications
As mentioned in the previous section, the recent structural insights in bacterial ribosomes shed light on the read-through mechanism in bacterial systems. However, unfortunately, up to this date, a little is known about the read-through mechanism in eukaryotes. Recent structural work revealed the three dimensional structures of the 80S yeast ribosome 111, 112 and the 40S, 60S subunits of the protozoa Tetrahymena thermophila 113, 114 at relatively high resolutions. More recent papers supplied the X-ray structures of 40S ribosomal subunits purified from rabbit reticulocytes at ~8Å resolutions 115 . This recent structural information opens a variety of opportunities underling the variance in eukaryotic vs.
prokaryotic translation mechanisms altogether with unlimited possibilities to explore the interactions of small molecules, such as AGs, with eukaryotic ribosomes. Nevertheless, one mustn't forget that this field is still very fresh and the study of complex molecules such as ribosomes still remains very complicated. In addition no structure of eukaryotic ribosome in complex with active small molecules such as AGs is presently available.
The recent work published by Shalev et. al. 43 demonstrated the binding of two AGs (G418 and apramycin) to their putative binding site in Leishmania ribosomes. Leishmania is a eukaryotic parasite sharing a great A-site similarity with human ribosomes (Fig. 4) . In this work, it has been shown for the first time that AGs exhibiting misreading activities in bacteria and read-through activities in human, such as G418, are potent inhibitors of Leishmanial growth and are able to induce the flip out of the two conserved adenine residues, A1492 and A1493, in the leishmanial A-site. The obtained conformation was identical to the one observed upon G418 binding to bacterial species (Fig. 10) . These results support the notion that AGs read-through activity in eukaryotes might be similar to those observed in prokaryotes. In addition, the paper highlights that upon apramycin's binding to the same Asite construct, only one of the two conserved adenines (A1493) is directed outside the helical core, whereas the other adenine residue (A1492) is maintained into the helical core and forms some electrostatic interactions with the G1408 residue. These results correlate well with additional structural work presented by Kondo et. al 84, 116 and Hermann et. al. 86 demonstrating similar conformations of two different human A-site models upon apramycin binding or upon NB33, a semi-synthetic derivative generated in our lab, binding (Fig. 10) .
Since both apramycin and NB33 are known to lack any read-through or misreading activity and in addition, apramycin was found not to cause leishmanial growth inhibition, this data 16 might supply an indirect support for the suggested readthrough mechanism of AGs action in eukaryotes, implying for the importance of the full flipping out of the two conserved adenine residues (A1492 and A1493) in order to achieve a read-through and/or misreading activities.
To conclude this section, despite no actual evidence exists, the evolutional conservancy of active ribosomal locations such as the decoding center and the peptidyl transferase center imply for a rather high similarity between the read-through mechanisms in prokaryotes to those observed in eukaryotes; therefore, the structural insights available in prokaryotes might serve as a putative base for understanding the molecular mechanisms by which AGs induce read-through events in eukaryotes.
Summary and Outlook
This abbreviated overview highlights that AGs hold great potential to serve as altogether with the recent development in eukaryotic ribosome structures it is likely to assume that these mechanisms share great similarity. However, further deep investigations are still needed to be performed in order to establish their mechanism of action in eukaryotic system and make it practicable for rational drug design.
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Figure 2:
A comparison of the (A) normal translation process leading to functional protein production, (B) translation which is interrupted by a premature termination codon (PTC) leading to a truncated non-functional protein production, and (C) translation process which was restored by a read-through inducing compound such as an aminoglycoside. Terminal codons and PTCs are highlighted in yellow, aminoglycoside in green.
Figure 3:
The molecular mechanism in which 6'-OH aminoglycosides may interact with guanine 1408. A 2D representation of ring I of G418 interactions with A/G residue in 1408 position. Chronological development of lead compounds on the pseudo-trisaccharide (compound 1) scaffold by systematic optimization of structure-activity-toxicity relationship as follow: firstgeneration lead (compound 1, also called NB30) 68 was developed by attaching 5-amino ribose at C5 position of the paromamine (rings I and II of paromomycin); second-generation compound 2 (also called NB54), 69 by further attaching (S)-4-amino-2-hydroxybutanoyl Structures of natural (apramycin) and semi-synthetic (NB33) aminoglycosides with high selectivity towards eukaryotic systems. The 2-deoxystreptamine (2-DOS) ring is highlighted in blue.
Figure 7:
Chemical structures of non-aminoglycoside read-through inducers.
Figure 8:
Schematic view of translation elongation and translation termination with magnified elements from ribosome crystal structures. (A) Molecular glance at the bacterial decoding site upon cognate tRNA binding -'ON' state. The 30S ribosomal subunit is showed at the left side with three tRNA molecules bound (A-site -green; P-site -Yellow; E-site -Blue) and mRNA highlighted in black. The A-site tRNA is bound to an EF (elongation factor -light pink) which is an intrinsic protein participating in the translation elongation process. The actual decoding site is highlighted in red, and is enlarged in the right side of the figure. The mRNA in the enlarged view is highlighted in yellow; A-site bound tRNA in green; and the two conserved adenine residues, A1492 and A1493, flipping out from the helical core, are highlighted in blue and red, respectively. The PDB entry for the presented structure is 2WRQ.
(B) Structural view of the bacterial decoding site during termination, with mRNA highlighted in black; P-site and E-site tRNA molecules highlighted in green and blue, respectively; and RF highlighted in red. The decoding site is highlighted in yellow and an enlarged representation is presented in the right side of the figure. In the enlarged object RF is highlighted in red; mRNA in gold; and the conserved adenine residues A1492 and A1493 in blue and purple, respectively. The PDB entry for the presented structure is 2X9R.
Figure 9:
The read-through mechanism. (A) Schematic representation of the read-through mechanism at the molecular level as indicated from recent X-ray structures (top panel). The structure at the bottom panel presents the A-site conformation upon AG (paromomycin) binding with the two conserved adenine residues (A1492-blue and A1493-red) bulging out from the helical core. PTC denotes Premature Termination Codon. (B) Superposition of the bacterial ribosome structure with the AG paromomycin (yellow sticks) bound to the A-site (PDB ID: 3IBL) and RF bound to the bacterial ribosome (PDB ID: 2X9R). The structure demonstrates the clashing of A1493 (red) with the Cα backbone of the RF (green), therefore suggests for a steric hindrance of RF to the A-site upon the induced conformation when AG is bound to the bacterial A-site.
